Skip to main content

Table 1 Basal characteristic, clinical features, empirical antimicrobial treatment and outcomes of included patients and analysis of existing differences between older and non-older patients with a febrile urinary tract infection

From: Characteristics of febrile urinary tract infections in older male adults

CharacteristicsaAll patients (n = 552)Older (n = 329)Non-older (n = 223)P value
Baseline conditions
 Age (years)66.1 + 16.777.3 + 7.649.5 + 12.2<  0.001
 HCA-FUTI203 (36.8)177 (53.8)26 (11.7)s<  0.001
  Previous hospital admission130 (23.6)114 (34.7)16 (7.2)<  0.001
  Long term care facility46 (8.3)43 (13.1)3 (1.3)<  0.001
  IV home-day hospital treatment13 (2.4)9 (2.7)4 (1.8)0.47
  Specialized nursing care7 (1.3)6 (1.8)1 (0.4)0.25
  Indwelling urinary catheter76 (13.8)66 (20.1)10 (4.5)<  0.001
   Long-term IUC40 (7.2)33 (10)7 (3.1)0.002
   Short- term IUC36 (6.5)33 (10)3 (1.3)<  0.001
  Invasive urinary intrumentation110 (19.9)98 (29.8)12 (5.4)<  0.001
 Dementia64 (11.6)62 (18.8)2 (0.9)<  0.001
 Diabetes mellitus148 (26.8)113 (34.3)35 (15.7)<  0.001
 Chronic kidney failure54 (9.8)49 (14.9)5 (2.2)<  0.001
 Cirrhosis9 (1.6)5 (1.5)4 (1.8)1
 Neoplasia81 (14.7)72 (21.9)9 (4)<  0.001
 Heart failure8 (1.4)7 (2.1)1 (0.4)0.15
 Chronic obstructive lung disease100 (18.1)90 (27.4)10 (4.5)<  0.01
 Immunosuppressive or corticosteroid treatment11 (2)7 (2.1)4 (1.8)1
 Charlson score3.6 + 2.55.1 + 1.71.3 + 1.6<  0.001
 Previous UTI222 (45.5)152 (53.7)70 (34.1)<  0.001
 Urinary tract abnormality339 (61.5)252 (76.8)87 (39)<  0.001
  BPH239 (43.4)187 (57)52 (23.3)<  0.001
  Urogenital cancer48 (8.8)44 (13.6)4 (1.8)<  0.001
 Previous antibiotic treatment179 (32.6)135 (41.3)44 (19.8)<  0.001
  Aminopenicillins60 (11)42 (13)18 (8.2)0.081
  Fluoroquinolones54 (9.9)41 (12.7)13 (5.9)0.010
  TGC16 (2.9)11 (3.4)5 (2.3)0.44
  Fosfomycine10 (1.8)9 (2.8)1 (0.5)0.055
Clinical presentation
 LUTS359 (65.3)172 (52.4)187 (84.2)<  0.001
 Flank pain89 (16.2)31 (9.5)58 (26.1)<  0.001
Physical examination
 Temperature37.7 + 137.7 + 1.137.7 + 0.90.85
 MAP (mmHg)93.4 + 15.391.1 + 15.396.9 + 14.7<  0.001
 Lumbar tenderness94 (22.1)40 (17.3)54 (27.7)0.010
 Prostatic tenderness81 (42.6)35 (37.2)46 (47.9)0.13
Laboratory
 WBC count (leukocytes/mm3)13,903 + 574313,348 + 553614,759 + 59610.006
 Creatinine (mg/dl)1.2 + 0.71.4 + 0.81.1 + 0.4<  0.010
 Bacteremia120 (31.6)92 (38)28 (20.3)<  0.010
Treatment
 Empirical treatment with TGC307 (55.6)176 (53.5)131 (58.7)0.22
 Empirical treatment with carbapenems or PT59 (10.7)46 (14)13 (5.8)0.002
 IEAT95 (17.2)69 (21)26 (11.7)0.004
 OPAT71 (12.9)54 (16.4)17 (7.6)0.002
Outcomes
 Severe sepsis or septic shock17 (3.1)12 (3.6)5 (2.2)0.35
 Hospital admission266 (48.2)197 (59.9)69 (30.9)<  0.001
 Length of hospitalisation (days)2.6 + 4.13.3 + 4.61.4 + 2.9<  0.001
 Length antimicrobial therapy (days)16.3 + 6.716 + 716.8 + 6.50.19
 All-cause in-hospital mortality15 (2.7)14 (4.3)1 (0.4)0.007
 Attributable in-hospital mortality8 (1.4)8 (2.4)00.024
  1. Abbreviations: BPH Benign prostatic hyperplasia, HCA-FUTI Healthcare-associated febrile urinary tract infection, IEAT Inadequate empirical antimicrobial treatment, IUC Indwelling urinary catheter, LUTS Lower urinary tract symptoms, MAP Mean arterial pressure, OPAT Outpatient parenteral antimicrobial therapy, PT Piperacillin-tazobactam, TGC Third-generation cephalosporins, UTI Urinary tract infections, WBC White blood cell
  2. aData presented as mean + standard deviation (SD) or numbers of patients (percentages)